Because of the involvement of both the mechanisms, treatment with GLP-1 is unlikely to interfere grossly with the glucagon-mediated defense against hypoglycemia.[3] Moreover, though GLP-1 decreases glucagon secretion in hyperglycemia, it does not do so in hypoglycemia; rather it may increase it.[7] This is particularly important and beneficial, because most of the currently used antidiabetic agents posses the risk of hypoglycemia.[19] Added to this, GLP-1 does not increase insulin release at normal blood glucose concentrations and hence, does not cause hypoglycemia.[20]. The gene discussed is GCG; the disease is Hyperglycemia.